Geode Capital Management, LLC Instil Bio, Inc. Transaction History

Geode Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.4 - $0.63 $36,586 - $57,622	91,465 Added 16.03%	662,038 $284,000
Q2 2023 Aug 11, 2023	SELL	$0.51 - $0.67 $328,678 - $431,792	-644,467 Reduced 53.04%	570,573 $313,000
Q1 2023 May 15, 2023	BUY	$0.6 - $0.91 $25,830 - $39,176	43,051 Added 3.67%	1,215,040 $801,000
Q4 2022 Feb 13, 2023	SELL	$0.48 - $5.33 $15,687 - $174,195	-32,682 Reduced 2.71%	1,171,989 $738,000
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.37 $1.87 Million - $2.97 Million	402,504 Added 50.18%	1,204,671 $5.83 Million
Q2 2022 Aug 12, 2022	BUY	$4.21 - $11.15 $543,043 - $1.44 Million	128,989 Added 19.16%	802,167 $3.71 Million
Q1 2022 May 13, 2022	BUY	$8.48 - $18.1 $173,475 - $370,271	20,457 Added 3.13%	673,178 $7.24 Million
Q4 2021 Feb 11, 2022	BUY	$15.37 - $22.5 $3.6 Million - $5.28 Million	234,533 Added 56.08%	652,721 $11.2 Million
Q3 2021 Nov 12, 2021	BUY	$15.05 - $23.28 $206,651 - $319,657	13,731 Added 3.39%	418,188 $7.48 Million
Q2 2021 Aug 13, 2021	BUY	$15.31 - $24.63 $4.83 Million - $7.77 Million	315,611 Added 355.23%	404,457 $7.81 Million
Q1 2021 May 12, 2021	BUY	$24.23 - $27.06 $2.15 Million - $2.4 Million	88,846 New	88,846 $2.23 Million

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $2.67B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.